1. Home
  2. EDSA vs XLO Comparison

EDSA vs XLO Comparison

Compare EDSA & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Edesa Biotech Inc.

EDSA

Edesa Biotech Inc.

HOLD

Current Price

$2.94

Market Cap

51.5M

Sector

Health Care

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$8.49

Market Cap

56.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDSA
XLO
Founded
2015
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.5M
56.9M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
EDSA
XLO
Price
$2.94
$8.49
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $16.33
N/A
AVG Volume (30 Days)
★ 37.3K
8.6K
Earning Date
08-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 589.88
52 Week Low
$0.72
$0.46
52 Week High
$20.32
$25.17

Technical Indicators

Market Signals
Indicator
EDSA
XLO
Relative Strength Index (RSI) 31.82 43.16
Support Level $0.83 $8.52
Resistance Level $4.27 $8.80
Average True Range (ATR) 0.34 0.33
MACD -0.08 -0.03
Stochastic Oscillator 15.43 22.16

Price Performance

Historical Comparison
EDSA
XLO

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: